Beijing Beilai Biosciences

Beijing Beilai Biosciences is a clinical-stage biotechnology company headquartered in Beijing, China, specializing in the development of advanced stem cell therapies. The company focuses on utilizing human umbilical cord mesenchymal stem cells (UC-MSCs) and induced pluripotent stem cells (iPSCs) to treat life-threatening conditions such as chronic-on-acute liver failure and graft-versus-host disease. Beilai Biosciences operates a comprehensive R&D and manufacturing infrastructure that adheres to GMP standards for cell-based medicinal products. Their pipeline includes several candidates currently undergoing clinical evaluation in China, aiming to address significant unmet medical needs in regenerative medicine. The company is recognized for its robust technical platform and has received multiple IND clearances from the NMPA.